...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz.
【24h】

Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz.

机译：简短交流：接受依法韦仑治疗的接受HAART的HIV / AIDS患者的口腔病变。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Oral lesions (OL) have an important prognostic value for HIV/AIDS patients. However, the behavior of OL in HIV/AIDS patients undergoing highly active antiretroviral therapy including efavirenz (HAART/EFV) has not been documented. Our objective was to establish the prevalence of OL in HIV/AIDS patients undergoing HAART/EFV and to compare it with the prevalence of OL in patients undergoing antiretroviral therapy including a protease inhibitor (HAART/PI). Seventy-three HIV/AIDS patients undergoing antiretroviral treatment for at least for 6 months at "La Raza" Medical Center's Internal Medicine Unit (IMSS, Mexico City) were included. To detect OL, a detailed examination of oral soft tissues was performed in each patient. Patient records recorded gender, seropositivity time, route of contagion, antiretroviral therapy type and duration, CD4 lymphocyte count/ml, and viral load. Two groups were formed: 38 patients receiving HAART/EFV [two nucleoside analogue reverse transcriptase inhibitors (NARTI) plus efavirenz] and 35 patients receiving HAART/PI (two NARTIs plus one PI). OL prevalence was established in each study group. The Chi-square test was applied (p 0.05(IC95%)). OL prevalence in the HAART/EFV group (32%) was lower (p 0.007) than in the HAART/PI group (63%). Candidosis was the most prevalent OL in both groups. Herpes labialis, HIV-associated necrotizing periodontitis, xerostomia, hairy leukoplakia, and nonspecific oral sores were identified. The highest prevalence for all OL was found in the HAART/PI group. These findings suggest that HIV/AIDS patients undergoing HAART/EFV show a lower prevalence of oral lesions than patients undergoing HAART/PI.
机译：口腔病变（OL）对HIV / AIDS患者具有重要的预后价值。然而，OL在接受包括依非韦伦（HAART / EFV）在内的高活性抗逆转录病毒疗法的HIV / AIDS患者中的行为尚未得到证实。我们的目标是确定接受HAART / EFV的HIV / AIDS患者的OL患病率，并将其与接受包括蛋白酶抑制剂（HAART / PI）的抗逆转录病毒治疗的OL患病率进行比较。包括73名在“ La Raza”医学中心内科（墨西哥城，IMSS）接受抗逆转录病毒治疗至少6个月的HIV / AIDS患者。为了检测OL，对每位患者进行了口腔软组织的详细检查。患者记录记录了性别，血清反应阳性时间，传染途径，抗逆转录病毒疗法的类型和持续时间，CD4淋巴细胞计数/ ml和病毒载量。分为两组：38例接受HAART / EFV [两种核苷类似物逆转录酶抑制剂（NARTI）加依非韦伦]的患者和35例接受HAART / PI（两种NARTIs加一种PI）的患者。在每个研究组中都确定了OL患病率。应用卡方检验（p <0.05（IC95％））。 HAART / EFV组的OL患病率（32％）低于HAART / PI组的（63％）（p <0.007）。念珠菌病是两组中最普遍的OL。鉴定出了唇疱疹，HIV相关性坏死性牙周炎，口干症，毛白斑和非特异性口腔溃疡。在HAART / PI组中发现所有OL的患病率最高。这些发现表明，接受HAART / EFV治疗的HIV / AIDS患者的口腔病变患病率低于接受HAART / PI的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号